SUGGESTED FORMULA

Dithranol 1% in Lipid-Cream
Version number: 1.0
Volume or quantity: 100 gm

Dithranol	1 g
Glyceryl Myristate	21 g
Glyceryl Laurate	7 g
Citric Acid (Anhydrous) (CI131)	1 g
Sodium Hydroxide	140 mg
Water, Purified USP	QS 100g

NOTES: Use glass or plastic equipment when working with this preparation; avoid contact with metal utensils. This preparation should be prepared in a vertical airflow hood in a biological safety cabinet or barrier isolation technology.

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient. Do NOT use metal equipment to come in contact with Dithranol.
3. Heat the Glyceryl Laurate and Glyceryl Myristate to about 70°C and incorporate the Dithranol powder. Glyceryl Laurate and Glyceryl Myristate in combination have a melting point in the range of about 30°C to 32°C.
4. Heat the citric acid and sodium hydroxide in 70mL or purified water to 70°C
5. Add the oil phase (step#3) to the aqueous phase (step#4) and mix well; continue heating at 70°C for 15 minutes.
6. Cool the mixture to about 40°C
7. Slowly continue cooling the mixture to room temperature while stirring; this is a controlled cooling step.
8. Package and label
9. Suggested Quality assessments:
    a. color
    b. texture
    c. container

d. Label - auxiliary labels, storage, BUD, compounded medication

Store in light resistant air-tight container, at Controlled room temperature

***Pregnant women must not handle this medication * Keep away from eyes and mucous membranes**

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-use date should be assigned based on the current USP Chapter <795> guidelines.

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.
9/19 JD